^
Association details:
| Biomarker: | EGFR G719A |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable complete response in leptomeningeal disease (LMD) of EGFR mutated non-small cell lung cancer (NSCLC) to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib
Published date:
01/28/2023
Excerpt:
A 67-year-old male presented with recently diagnosed advanced NSCLC….Tissue next-generation sequencing (NGS) demonstrated EGFR G719A (exon18 substitution) mutation….6 months after starting amivantamab, the patient was found to have complete resolution of CNS disease, including LMD. Drastic improvement in his functional status was observed during this period....He has received amivantamab for more than 14 months, and his scans continue to show durable responses in the primary lung lesion with no evidence of CNS disease.
Source:
Title:
4113 / 28 - Response to amivantamab, a bispecific EGF and MET receptor directed antibody, in a patient with an atypical EGFR mutated (G719X) non-small cell lung cancer (NSCLC) with leptomeningeal disease who progressed on osimertinib
Published date:
03/09/2022
Excerpt:
A 67-year-old male presented with stage IVB squamous cell carcinoma of lung with osseous metastases….Tissue next generation sequencing (NGS) showed EGFR G719A….Amivantamab monotherapy was initiated...Repeat scans in 6 weeks showed decreased leptomeningeal enhancement, and reduction in the size of parenchymal lesions, lung mass, and lymphadenopathies....Amivantamab monotherapy has shown an encouraging outcome in a patient with an atypical EGFR mutated (G719X) NSCLC with leptomeningeal disease who progressed on osimertinib.
Test:
